Immortalization and characterization of a new canine mammary tumour cell line FR37‐CMT |
| |
| Authors: | L R Raposo C Roma‐Rodrigues P Faísca M Alves J Henriques M C Carvalheiro M L Corvo P V Baptista A J Pombeiro A R Fernandes |
| |
| Institution: | 1. UCIBIO, Departamento de Ciências da Vida, Faculdade de Ciências e Tecnologia, Universidade Nova de Lisboa, Caparica, Portugal;2. Centro de Química Estrutural, Complexo I, Instituto Superior Técnico, Universidade de Lisboa, Lisbon, Portugal;3. Centro de Investiga??o em Biociências e Tecnologias da Saúde (CBiOS), Faculdade Medicina Veterinária, Universidade Lusófona de Humanidades e Tecnologias (ULHT) Lisbon, Portugal;4. Oncovet Veterinary Clinic, Lisbon, Portugal;5. Research Institute for Medicines (iMed.ULisboa), Faculdade de Farmácia, Universidade de Lisboa, Lisbon, Portugal |
| |
| Abstract: | Here we describe the establishment of a new canine mammary tumour (CMT) cell line, FR37‐CMT that does not show dependence on female hormonal signaling to induce tumour xenografts in NOD‐SCID mice. FR37‐CMT cell line has a stellate or fusiform shape, displays the ability to reorganize the collagen matrix, expresses vimentin, CD44 and shows the loss of E‐cadherin which is considered a fundamental event in epithelial to mesenchymal transition (EMT). The up‐regulation of ZEB1, the detection of phosphorylated ERK1/2 and the downregulation of DICER1 and miR‐200c are also in accordance with the mesenchymal characteristics of FR37‐CMT cell line. FR37‐CMT shows a higher resistance to cisplatin (IC50>50 µM) and to doxorubicin (IC50>5.3 µM) compared with other CMT cell lines. These results support the use of FR37‐CMT as a new CMT model that may assist the understanding of the molecular mechanisms underlying EMT, CMT drug resistance, fostering the development of novel therapies targeting CMT. |
| |
| Keywords: | canine mammary tumours cisplatin doxorubicin epithelial to mesenchymal transition miRNAs |
|
|
